113140-16-2Relevant academic research and scientific papers
Synthesis of 3-phenylpyrazolo[4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-releasing factor receptor type-1 antagonists
Wilcoxen, Keith,Huang, Charles Q.,McCarthy, James R.,Grigoriadis, Dimitri E.,Chen, Chen
, p. 3367 - 3370 (2007/10/03)
3-Phenylpyrazolo[4,3-b]pyridines were synthesized via a cyclization of 4-amino-3-phenylpyrazoles 11-13 with ethyl acetoacetate. These compounds were found to be potent CRF1 antagonists. The 2-alkylpyrazolo[4,3-b]pyridines were more polar but le
Pharmaceutically useful pyrazolo[4,3-b]pyridines
-
, (2008/06/13)
A compound of the formula (I) or a salt or solvate thereof: STR1 in which: R0 is hydrogen or C1-6 alkyl; or together with R3 is C4-6 polymethylene; R1 and R2 are both hydrogen; or R1 is hydrogen, C1-6 alkyl; and R2 is CN; CR5 R6 Y where R5 and R6 are independently selected from hydrogen and C1-4 alkyl and Y is selected from hydrogen, OR7 or SR7 where R7 is hydrogen, C1-4 alkyl or C2-4 alkanoyl, and NR8 R9 where R8 and R9 are independently hydrogen, C1-4 alkyl, C2-4 alkenyl or C2-4 alkanoyl or together are C4-6 polymethylene; or COR10 where R10 is OH or C1-4 alkyl, or COR10 is a pharmaceutically acceptable ester or amide, or R2 is hydrogen, C1-6 alkyl, or phenyl optionally substituted by halogen, CF3, C1-4 alkoxy or C1-4 alkyl, and R1 is CN, CR5 R6 Y or COR10 as defined for R2 above; or R1 and R2 together form C3 -C6 polymethylene optionally substituted by C1 -C4 alkyl; R3 is hydrogen; or C1-10 alkyl or C3-10 cycloalkyl, either optionally substituted by hydroxy, C1-4 alkoxy, thiol, C1-4 alkylthio or NR11 R12 wherein R11 and R12 are independently hydrogen, C1-6 alkyl or C2-7 alkanoyl or together are C3-6 polymethylene; C2-10 alkenyl; or phenyl optionally substituted by one or two of halogen, CF3, C1-4 alkoxy, C1-4 alkyl, hydroxy, nitro, cyano, C2-10 acyloxy, NR13 R14 wherein R13 and R14 are independently selected from hydrogen, C1-6 alkyl, or C2-7 alkanoyl; or COR15 wherein R15 is hydroxy, C1-6 alkoxy or NR16 R17 wherein R16 and R17 are independently selected from hydrogen or C1-6 alkyl; or R3 is a mono- or fused bi-cyclic heteroaryl group having up to ten atoms in the aromatic ring(s), not more than two of which are selected from nitrogen, oxygen or sulphur, other than those containing basic nitrogen, optionally substituted by one or two substituents selected from halogen, CF3, C1-4 alkoxy, C1-4 alkyl, hydroxy, nitro, cyano, C2-10 acyloxy, NR23 R24 wherein R23 and R24 are independently selected from hydrogen, C1-6 alkyl, C2-7 alkanoyl or C1-6 alkylsulphonyl; or COR25 wherein R25 is hydroxy, C1-6 alkoxy or NR26 R27 wherein R26 and R27 are independently selected from hydrogen or C1-6 alkyl; R4 is hydrogen, or C1-4 alkyl, phenyl or benzyl, each of which is optionally substituted in the phenyl ring by one or two of halogen, CF3, C1-4 alkoxy or C1-4 alkyl and is attached at nitrogen atom 1 or 2; and Rx is C1-6 alkyl, halogen, nitro, NR18 R19 where R18 and R19 are independently hydrogen, C1-6 alkyl or C2-7 alkanoyl, nitrile, COOH, CONH2 ; phenyl or benzyl optionally substituted by one or two of halogen, nitro, C1-6 alkoxy, hydroxy, C2-7 alkanoyloxy, NR18 R19, C1-6 alkyl, CF3, CN; thienyl, furyl or pyrryl optinoally N-substituted by C1-6 alkyl, with the proviso that R0 and R3 are not both hydrogen when R1 is hydrogen and R2 and Rx are methyl, is useful for treating inflammatory or allergic conditions.
